Skip to main content
TipRanks
Go Ultimate75% OFF

Glenmark Life Sciences Limited (ALIVUS) AI Stock Analysis

6 Followers
IN:ALIVUS

Glenmark Life Sciences Limited

(NSE:ALIVUS)

Select Model
Rating:80Outperform
Price Target:INR 1,671.00â–²(15.36% Upside)
Action:reiterated
Date:11/12/26

Strong financial performance with low leverage and steady profitability is the primary driver, reinforced by bullish technical indicators from moving averages and MACD.

Positive Factors
Revenue AccelerationThe sharp FY2026 revenue acceleration indicates stronger commercial demand and expanding business activity across the API portfolio. If sustained, higher scale can improve capacity utilization, reinforce customer relationships, and provide a durable base for continued earnings growth over the next several quarters.
Negative Factors
Weak Free-Cash-Flow ConversionFree cash flow materially below net income indicates that working-capital requirements or capital spending are absorbing a meaningful portion of reported earnings. This can limit internally funded expansion and makes cash generation less dependable than the company’s strong accounting profitability suggests.

Glenmark Life Sciences Limited (ALIVUS) vs. iShares MSCI India ETF (INDA)

-20%0%20%40%60%80%IN:ALIVUS+60.09%INDA-5.59%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 178.44B
Dividend Yield
0.35%
Average Volume (3M)
26.10K
Price to Earnings (P/E)
26.6
Beta (1Y)
0.94
Revenue Growth
8.19%
EPS Growth
26.12%
Country
India
Employees
2,272
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Glenmark Life Sciences Limited Business Overview & Revenue Model

Company Description

Alivus Life Sciences Limited, a Mumbai, India-headquartered entity established in 2001, operates as a subsidiary of Nirma Limited. Having rebranded from Glenmark Life Sciences Limited in December 2024, the company specializes in the development, prod...

How the Company Makes Money

Glenmark Life Sciences primarily makes money by selling APIs and intermediates to pharmaceutical companies that use these materials to manufacture finished-dose medicines. Revenue is generated through (1) commercial supply of APIs for generic and bra...

Glenmark Life Sciences Limited Financial Statement Overview

Summary

Robust revenue and net income growth, significantly strengthened balance sheet with near-zero debt-to-equity, and consistent operating cash flow generation.

Income Statement

85Very Positive

Balance Sheet

90Very Positive

Cash Flow

80Positive
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024Mar 2022Mar 2021Mar 2020
Income Statement
Total Revenue11.91B25.52B22.83B21.61B18.85B15.37B
Gross Profit5.31B11.37B12.43B11.47B9.80B8.47B
EBITDA3.68B8.32B6.86B6.71B5.92B4.84B
Net Income2.53B5.64B4.71B4.67B3.52B3.13B
Balance Sheet
Total Assets36.38B39.83B28.50B27.02B19.97B17.26B
Cash, Cash Equivalents and Short-Term Investments6.53B7.83B3.01B3.80B1.40B307.68M
Total Debt1.13B567.71M171.48M193.57M9.33B210.00K
Total Liabilities6.23B6.51B5.18B5.64B12.44B13.24B
Stockholders Equity30.15B33.32B23.32B21.38B7.53B4.02B
Cash Flow
Free Cash Flow913.92M2.59B2.85B1.43B3.20B1.44B
Operating Cash Flow1.72B5.66B4.14B3.13B3.88B1.95B
Investing Cash Flow-5.43B-5.71B-1.16B-1.54B-687.34M-505.18M
Financing Cash Flow-44.64M-641.34M-2.79B-3.88B-2.14B-1.37B

Glenmark Life Sciences Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price1448.50

Price Trends

50DMA1381.37Positive
100DMA1305.87Positive
200DMA1149.31Positive

Market Momentum

MACD32.28Negative
RSI57.55Neutral
STOCH34.30Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALIVUS, the sentiment is Positive. The current price of 1448.50 is above the 20-day moving average (MA) of 1393.70, above the 50-day MA of 1381.37, and above the 200-day MA of 1149.31, indicating a bullish trend. The MACD of 32.28 indicates Negative momentum. The RSI at 57.55 is Neutral, neither overbought nor oversold. The STOCH value of 34.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ALIVUS.

Glenmark Life Sciences Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:ALIVUS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:ALIVUSIN:ALIVUS80OutperformINR 178.12B26.56―0.35%8.19%26.12%
IN:DIVISLABIN:DIVISLAB74OutperformINR 2.95T87.44―0.27%21.56%35.33%
IN:GRANULESIN:GRANULES72OutperformINR 198.15B27.64―0.22%21.75%36.70%
IN:LAURUSLABSIN:LAURUSLABS67NeutralINR 1.20T89.48―0.10%23.03%95.69%
IN:NEULANDLABIN:NEULANDLAB60NeutralINR 277.40B61.35―0.16%50.46%88.44%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:SOLARAIN:SOLARA50NeutralINR 30.50B82.34――27.30%456.80%

* General Sector Average

Performance Comparison

0%50%100%IN:ALIVUSIN:DIVISLABIN:GRANULESIN:LAURUSLABSIN:NEULANDLABIN:SOLARADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ALIVUS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ALIVUSGlenmark Life Sciences Limited1448.50530.2857.75%
IN:DIVISLABDivi's Laboratories Limited11111.004662.3572.30%
IN:GRANULESGranules India Limited799.65239.0242.63%
IN:LAURUSLABSLaurus Labs Ltd.2217.051212.48120.70%
IN:NEULANDLABNeuland Laboratories Ltd.21621.354402.9325.57%
IN:SOLARASolara Active Pharma Sciences Ltd.634.4561.6510.76%

Glenmark Life Sciences Limited Corporate Events

Alivus Executes Shareholders’ Agreement With IQGEN-X Pharma

Nov 11, 2026

Alivus Life Sciences executed a shareholders’ agreement with IQGEN-X Pharma and its continuing existing shareholders, Dr. Mandar Kodgule and Dr. Yogita Kodgule. The agreement records mutual understanding on shareholding-related rights and obligations...

Alivus Life Sciences posts double-digit growth and record margins in Q2FY27

Oct 29, 2026

Alivus Life Sciences reported strong results for the quarter ended September 30, 2026, with revenue from operations rising 16.0% year-on-year to Rs. 6,820 million, driven by broad-based momentum in its non-GPL API business and a meaningful pickup in...

Alivus Life Sciences Files Q2 FY26-27 Investor Presentation with Stock Exchanges

Oct 29, 2026

Alivus Life Sciences Limited has released its investor presentation for the second quarter of fiscal year 2026-27, complying with disclosure requirements under Indian securities regulations. The filing with BSE and NSE signals routine quarterly commu...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026